AUSTRAL Dx is a French MedTech startup created in 2021. It develops the first medical device using airborne ultrasound for the screening, diagnosis, and monitoring of cardiac and pulmonary pathologies in acute or chronic situations.
AUSTRAL Dx's technology has the potential to accelerate the paradigm shift towards early diagnosis and preventive care.
The first device developed by AUSTRAL Dx will be intended for emergency services to speed up the diagnosis of patients presenting with symptoms such as dyspnea or chest pain.
"The problem faced by emergency physicians when confronted with respiratory symptoms such as dyspnea is to determine the origin as quickly as possible."
Head of Emergency Services at Avicenna Hospital (AP-HP)
"Having a tool that easily detects people with heart failure would be a significant advancement in the prevention of these diseases."
Cardiologist at HEGP, AP-HP
"The device is not intended to replace an examination (chest X-ray, pulmonary ultrasound, or ECG) but to avoid it when unnecessary in emergency situations. It would provide additional data to the emergency physician and assist in defining the diagnostic strategy."
Head of Pulmonology and Intensive Care at Pitié Salpêtrière, AP-HP
On Thursday, 24 July 2025, AUSTRAL Dx announced the completion of a €2.5 million seed round led by Sorbonne Venture by Audacia and Aloe Private Equity, with participation from iXcore, Kima Ventures, Better Angle, Super Capital, Capital Cell, Paris Business Angels, Angels Santé, several individual business angels, as well as the support of Bpifrance / France 2030 via the i-Nov competition.
press release (in French)
Heart and lung health: promising preliminary results from the study to non-invasively diagnose lung and heart pathology, conducted by the Caen Normandie University Hospital in partnership with the start-up company AUSTRAL Dx. This is the first trial of this technology in a hospital setting.
view on LinkedIn